Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 23, 2014
- Accepted in final form February 10, 2015
- First Published March 12, 2015.
Author Disclosures
- Heather B. Streeter, PhD,
- Rachel Rigden, PhD,
- Keith F. Martin, PhD,
- Neil J. Scolding, PhD, FRCP and
- David C. Wraith, PhD
- Heather B. Streeter, PhD,
NONE
NONE
NONE
NONE
(1) Myelin basic protein peptide composition (2) Peptide composition (3)Tolerogenic peptides from myelin basic protein
NONE
(1) Apitove NV, Research Project Leader, 2009-2011
NONE
NONE
NONE
NONE
(1) Apitope NV
NONE
NONE
NONE
(1) Apitope NV, 2002-present
NONE
NONE
NONE
NONE
NONE
- Rachel Rigden, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
During this study I was employed by Apitope Technolgy, as a senior scientist for 2 years.
NONE
NONE
NONE
NONE
Apitope Technolgy
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Keith F. Martin, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Apitope Technology (Bristol) Ltd.; Chief Executive Officer
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Apitope International NV
NONE
NONE
NONE
NONE
NONE
- Neil J. Scolding, PhD, FRCP and
NONE
NONE
NONE
Practical Neurology; Assistant Editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research support from Genzyme-Sanofi, Merck Serono, Biogen and Novartis
NONE
NONE
The Silverman Foundation have funded research.
NONE
NONE
NONE
NONE
NONE
NONE
- David C. Wraith, PhD
Apitope Intl NV, Actelion Pharma and Zealand Pharma
NONE
NONE
Senior Editor: Immunotherapy: Current http://www.futuremedicine.com/page/journal/imt/editors.jsp
1. WO2014111841 (A2) ? PEPTIDE: Wraith, D., Streeter, H., Ordonez, L. 2014 2. WO2014111840 (A2) ? PEPTIDE: Wraith, D., Streeter, H. 2014 3. WO2014072958 (A1) ? PEPTIDES: Wraith, D., Streeter, H. 2014 4. WO2013150284 (A1) - TOLERISATION- INDUCING COMPOSITION: Wraith, D., Hill, E. 20135. WO2009071886 (A1) - FVIII PEPTIDES AND THEIR USE IN TOLERISING HAEMOPHILIACS: Wraith, D. 2009 6. WO2009056833 (A2) ? COMPOSITION: Wraith, D., Streeter, H.B. 2009 7. WO2008129296 (A2) ? DISEASE MARKERS: Wraith, D., Streeter, H. 2008 8. WO03064464 (A1) - TOLEROGENIC PEPTIDES FROM MYELIN BASIC PROTEIN: Ponsford, F.M., Mazza, G., Wraith, D.C., Streeter, H.B. 2003 9. WO0216410 (A3) ? PEPTIDE SELECTION METHOD: Wraith, D.C., Anderton, S.M., Mazza, G., Ponsford, M., Streeter, H.B. 2002 10.WO8604242 (A1) - IMPROVEMENTS RELATING TO INFLUENZA VACCINE: Askonas, B.A., Wraith, D.C. 1986
NONE
NONE
1. Has a consultancy agreement with Apitope International NV.2. Past Member of SAB for Peptide therapeutics, TEVA and GSK BIO (vaccine safety advisory board). Advisor to Hoffman La Roche on autoimmune therapeutics. Advisor to Novartis on Influenza Vaccine Adjuvant Safety. 3. Non-profit. Advisor to DTI on Stem Cell Therapies 4. Non-profit. Advisor to Food Standards Agency on Peanut Allergy
NONE
NONE
NONE
1. Apitope International NV and UCB Celltech.
MRC. MR/K007645/1. 2013-2016
NONE
Wellcome Trust Programme grant #09107
1. Apitope Intl. NV. Holds stock and stock options in Apitope Intl NV and receives travel costs for attending Apitope board meetings.
NONE
NONE
Apitope Intl NV 2006-Current
NONE
1. Geron, expert witness European Patent Court. 2007, 2011
- From Apitope Technology Bristol Ltd. (H.B.S., R.R., K.F.M., D.C.W.), Bristol UK; School of Cellular and Molecular Medicine (H.B.S., D.C.W.) and School of Clinical Sciences (N.J.S.), University of Bristol, UK; and Southmead Hospital (N.J.S.), Bristol, UK.
- Correspondence to Dr. Wraith: d.c.wraith{at}bris.ac.uk
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.